COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series

Roseanne Sullivan, Ajay Kilaru, Bernhard Hemmer, Bruce Anthony Campbell Cree, Benjamin M. Greenberg, Uma Kundu, Thomas Hach, Virginia DeLasHeras, Brian J. Ward, Joseph Berger

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

BACKGROUND AND OBJECTIVES: A descriptive analysis of COVID-19 infection in patients with multiple sclerosis (MS) receiving fingolimod or siponimod. METHODS: We reviewed the cases of COVID-19 from postmarketing or ongoing clinical trials reported to Novartis through December 27, 2020. RESULTS: As of December 27, 2020, 283 cases had been reported in fingolimod-treated patients. The mean age was 44 years (from n = 224; range 11-69 years), and 190 were women. Of 161 cases with available information, 138 were asymptomatic (6), mild (100), or moderate (32); 50 cases required hospitalization. At the last follow-up, 140 patients were reported as recovered/recovering, condition was unchanged in 22, and deteriorated in 3 patients; 4 patients had a fatal outcome. Information was not available for 114 patients. Of the 54 cases of COVID-19 reported in siponimod-treated patients, 45 were from the postmarketing setting and 9 from an ongoing open-label clinical trial. The mean age was 54 years (from n = 45; range 31-70), and 30 were women. Of 28 cases with available information, 24 were asymptomatic (2), mild (17), or moderate (5); 9 cases required hospitalization. At the last follow-up, 27 patients were reported as recovered/recovering, condition remained unchanged for 1, and 3 patients had a fatal outcome. Information was not available for 23 patients. DISCUSSION: Based on a review of available information, the risk of more severe COVID-19 in patients receiving fingolimod or siponimod seems to be similar to that reported in the general population and the MS population with COVID-19. However, limitations of spontaneous reporting, especially missing data, should be considered in the interpretation of these observations.

Original languageEnglish (US)
JournalNeurology(R) neuroimmunology & neuroinflammation
Volume9
Issue number1
DOIs
StatePublished - Nov 1 2021
Externally publishedYes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series'. Together they form a unique fingerprint.

Cite this